Andean Precious Metals (CVE:APM) Reaches New 1-Year High – What’s Next?

Andean Precious Metals Corp. (CVE:APM)’s share price hit a new 52-week high during trading on Friday . The company traded as high as C$1.83 and last traded at C$1.78, with a volume of 95385 shares traded. The stock had previously closed at C$1.70.

Analyst Ratings Changes

Separately, Desjardins upped their target price on Andean Precious Metals from C$1.60 to C$1.70 and gave the company a “buy” rating in a report on Tuesday, September 3rd.

Andean Precious Metals Stock Performance

The stock has a market cap of C$262.87 million, a price-to-earnings ratio of 4.63 and a beta of 1.22. The company has a fifty day moving average of C$1.25.

Andean Precious Metals (CVE:APM) last posted its quarterly earnings data on Tuesday, August 13th. The company reported C$0.08 earnings per share for the quarter, hitting analysts’ consensus estimates of C$0.08. The firm had revenue of C$95.47 million during the quarter. Andean Precious Metals had a net margin of 23.75% and a return on equity of 41.08%. On average, analysts anticipate that Andean Precious Metals Corp. will post 0.3806452 EPS for the current year.

Insider Activity at Andean Precious Metals

In other Andean Precious Metals news, insider 2176423 Ontario Ltd. purchased 204,600 shares of Andean Precious Metals stock in a transaction dated Monday, September 16th. The shares were acquired at an average price of C$1.14 per share, with a total value of C$233,141.70. Insiders bought 1,202,800 shares of company stock worth $1,607,032 in the last three months. 69.37% of the stock is owned by company insiders.

About Andean Precious Metals

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.